NDAORALCAPSULEPriority Review
Approved
Mar 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
6/8 — Strong
Priority Review
IMPAVIDO (miltefosine) by Knight Therapeutics is anti-leishmanial agent [see clinical pharmacology ( )] . Approved for leishmaniasis, cutaneous leishmaniasis, mucosal leishmaniasis and 1 more indications. First approved in 2014.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMPAVIDO (miltefosine) is an oral antileishmanial agent approved for treating cutaneous, mucosal, and visceral leishmaniasis. It works through an anti-leishmanial mechanism of action that disrupts parasite cell membranes. The drug represents a significant treatment option for parasitic infections endemic to tropical and subtropical regions.
$0.002BPart D
PeakProduct is at peak lifecycle stage with modest Part D utilization (36 claims in 2023), indicating a niche specialty market with stable but limited commercial growth opportunities.
Mechanism of Action
anti-leishmanial agent [see Clinical Pharmacology ( )] .
Pharmacologic Class:
Antileishmanial
Indications (4)
Worked on IMPAVIDO at Knight Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.